Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL: Low-dose Lopinavir/Ritonavir in Thai Children
NCT01307124Phase 3Completed
- Sponsor
- HIV-NAT
- Start
- Mar 2011
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lopinavir + ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by HIV-NAT. Primary endpoints: Proportion of participants with HIV RNA < 50 copies/ml at 48 weeks and Safety and tolerability at 48 weeks. Started Mar 2011; status: completed.
02
Drugs
lopinavir + ritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01307124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01307124.